Nexelis Acquires AIT Bioscience

Novotech to Acquire Agilex Biolabs from Healius to Expand Australian Bioanalytical Services

September 25, 2026

Healthcare Services

Novotech entered into an agreement to acquire Agilex Biolabs, an Adelaide-based Australian specialist bioanalytical laboratory business, from a wholly owned subsidiary of Healius. The deal is intended to expand Novotech’s laboratory capabilities in Australia and strengthen integrated clinical research and laboratory services for biotechnology and pharmaceutical clinical trial sponsors. Financial terms were not disclosed, and closing remains subject to customary regulatory conditions.

Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners

January 10, 2022

Healthcare Services

Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.

BioAgilytix Acquires 360biolabs and MicroConstants

October 14, 2021

Healthcare Services

BioAgilytix Labs, LLC acquired Australia-based 360biolabs and US-based MicroConstants to expand its global footprint and bioanalytical capabilities, including LC/MS/MS, virology and immunology expertise. The deals (360biolabs subject to FIRB approval) add capacity in Melbourne and Brisbane and establish BioAgilytix San Diego, strengthening support for first-in-human and early-phase clinical trials across major geographies.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

January 20, 2021

Biotechnology

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.

Nexelis to Acquire ImmunXperts

April 4, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.